 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2020 and provided business updates. During the last year, the power and potential of RNA medicines became clear to the world. Simultaneously, the Stoke team advanced our efforts to discover and develop RN 